查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403373

全基因组定序市场的全球市场预测（-2030）：按产品类型、工作流程、技术、应用、最终用户和地区进行分析

Whole Genome Sequencing Market Forecasts to 2030 - Global Analysis By Product (Consumables, Instruments and Services), Type (Small Whole Genome Sequencing & Large Whole Genome Sequencing), Workflow, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

2023年全球全基因组定序市场规模为452.8亿美元，预估2030年将达845.1亿美元，预测期间内复合年增长率为13.5%。

全基因组定序 (WGS) 是一种用于确定生物体基因组完整 DNA 序列的综合方法。基因组是DNA的完整集合，包括携带生物体发育、功能和维持的遗传资讯的所有基因和非编码区。全基因组定序在推动基因组学领域的研究和临床应用方面发挥着重要作用。

根据美国疾病管制与预防中心的统计，美国大约每 707 名新生儿中就有 1 人患有唐氏症，即约 5,568 名婴儿患有唐氏症。

遗传病患病率上升

WGS 是识别与各种疾病相关的遗传变异的强大工具。随着遗传病患疾病率的增加，对准确、全面的诊断方法的需求也随之增加。全基因组定序可以对个体的整个基因组进行彻底检查，从而深入了解疾病的遗传基础。 WGS 支持更了解潜在遗传机制的研究工作。此外，人们对早期检测和介入遗传疾病管理重要性的认识不断提高，也促进了对全基因组定序的需求。

在某些疾病状态下临床效用的局限性

某些疾病状态，特别是复杂和多因素的疾病，可能具有尚未明确定义或易于解决的遗传基础。在某些情况下，特定基因组观察与临床结果之间的关联尚未明确。缺乏可操作的资讯可能会限制全基因组定序的临床效用，医疗保健提供者可能很难使用遗传资料来指导治疗决策。它也引发了人们对如何处理此类情况的道德担忧。这阻碍了 WGS 融入临床实践。

肿瘤科招聘增加

全基因组定序可以对患者的基因组成进行全面分析，从而更好地了解癌症的分子驱动因素。它有助于识别促进癌细胞生长的特定基因突变或变化。 WGS资料在肿瘤学研究中的使用有助于确定合适的临床试验候选者。随着更多临床证据的产生以及该技术变得更容易获得和更具成本效益，WGS 在肿瘤学中的采用可能只会增加，从而推动市场扩张。

资料隐私和安全问题

基因组资料高度敏感，包含有关个体独特遗传倾向、疾病倾向和其他潜在个人特征的资讯。诈欺存取基因组资料的风险引起了人们对滥用敏感资讯的担忧。如果基因组资料落入坏人之手，它可以用于多种目的，包括身分盗窃、保险歧视和其他恶意活动。如果无法充分解决这些问题，可能会阻碍全基因组定序市场的成长。

COVID-19 的影响

COVID-19 大流行对全基因组定序市场产生了中性影响。这次大流行凸显了遗传学在理解和预防感染疾病方面的作用。世界各地的研究人员利用全基因组定序来研究 SARS-CoV-2 病毒的基因组成和演化历史。这凸显了遗传学在个体化治疗中的重要性。另一方面，市场暂时受到供应链中断、研究目标变化等变数的影响。

精准医疗领域预计将在预测期内成为最大的领域

精准医疗领域估计是一个利润丰厚的市场。精准医疗涉及根据每个患者的特征做出医疗和保健决策。全基因组定序在精准医学中发挥核心作用，提供个体整个基因组的全面分析。这有助于药物选择和给药优化。此外，它还提供具有成本效益的治疗、患者赋权和个体化护理计划，这些计划正在加速该细分市场的成长。

研究中心部门预计在预测期内复合年增长率最高。

由于广泛研究领域的进步，研究中心领域预计在预测期内将出现最高的复合年增长率。 WGS 在研究中心提供了无数的应用和优势，有助于对遗传学、基因组学和各种生物过程的批判性理解。它也为了解疾病机制、确定潜在的治疗标靶和开发个体化治疗方法提供了重要资讯。

比最大的地区

由于研发活动投资的增加，预计亚太地区在预测期内将占据最大的市场占有率。亚太地区的生物技术和医疗领域正在经历显着成长。各国政府启动了资助计画和支持政策，鼓励采用基因组技术进行研究和临床应用。该地区人口的多样化和常见疾病日益流行正在推动市场扩张。

复合年增长率最高的地区

由于政府财政支持的增加，预计北美在预测期内的复合年增长率最高。该地区拥有许多专注于基因组学和个人化医疗的大型生物技术和製药公司。北美消费者有兴趣了解他们的血统、某些健康状况的倾向以及其他基因组资讯。此外，全基因组定序及其在癌症治疗中的应用不断涌现的技术创新正在加强该地区的市场趋势。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场公司的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球全基因组定序市场：分产品

  • 消耗品
  • 装置
  • 服务

第六章全球全基因组定序市场：按类型

  • 小规模全基因组定序
  • 大规模全基因组定序

第七章全球全基因组定序市场：依工作流程

  • 资料分析
  • 顺序
  • 前序

第八章全球全基因组定序市场：依技术分类

  • Sanger序列
  • 微阵列
  • 聚合酶炼式反应
  • 下一代定序
  • 其他技术

第九章全球全基因组定序市场：依应用分类

  • 药物研发发现与开发
  • 诊断
  • 精准医疗
  • 其他用途

第十章 全球全基因组定序市场：依最终用户分类

  • 学术机构
  • 医院和诊所
  • 研究中心
  • 製药和生物技术公司
  • 其他最终用户

第十一章全球全基因体定序市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十二章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章 公司简介

  • Siemens Healthineers
  • Thermo Fisher Scientific Inc
  • F. Hoffmann-La Roche Ltd
  • Danaher Corporation
  • Agilent Technologies Inc
  • Illumina Inc
  • Complete Genomics
  • QIAGEN NV
  • GeneDx
  • Merck KGaA
  • Abbott
  • Eurofins Scientific
  • Oxford Nanopore Technologies
  • Bio-Rad Laboratories, Inc
  • Macrogens Inc
Product Code: SMRC24598

According to Stratistics MRC, the Global Whole Genome Sequencing Market is accounted for $45.28 billion in 2023 and is expected to reach $84.51 billion by 2030 growing at a CAGR of 13.5% during the forecast period. Whole Genome Sequencing (WGS) is a comprehensive method used to determine the complete DNA sequence of an organism's genome. The genome is the complete set of DNA, including all of the genes and non-coding regions that carry the genetic information for the development, functioning, and maintenance of an organism. Whole genome sequencing plays a critical role in advancing both research and clinical applications in the field of genomics.

According to the Centers for Disease Control and Prevention statistics, around 1 in every 707 newborn children in the U.S. suffer from Down syndrome, which accounts for approximately 5,568 children in the U.S.

Market Dynamics:

Driver:

Rising prevalence of genetic disorders

WGS is a powerful tool for identifying genetic variations associated with various disorders. As the prevalence of genetic disorders increases, there is a growing need for accurate and comprehensive diagnostic methods. WGS allows for a thorough examination of an individual's entire genome, providing insights into the genetic basis of diseases. It fuels the research efforts to better understand the underlying genetic mechanisms. Further, the rising awareness of the importance of early detection and intervention in managing genetic disorders contributes to the demand for WGS.

Restraint:

Limited clinical utility in certain conditions

In certain medical conditions, especially complex and multifactorial diseases, the genetic basis may not be well-defined or easily actionable. In some cases, the relevance of specific genomic findings to clinical outcomes may not be well-established. This lack of actionable information can limit the clinical utility of WGS, as healthcare providers may struggle to use the genetic data to inform treatment decisions. It also raises ethical concerns about how to handle such conditions. Thereby, it hinders the integration of WGS into clinical practice.

Opportunity:

Increasing adoption in oncology

Whole genome sequencing enables a comprehensive analysis of a patient's genetic makeup, allowing for a better understanding of the molecular drivers of cancer. It helps to identify specific genetic mutations and alterations that drive the growth of cancer cells. The use of WGS data in oncology research is instrumental in the identification of suitable candidates for clinical trials. As more clinical evidence is generated, and the technology becomes more accessible and cost-effective, the adoption of WGS in oncology is likely to continue its upward trajectory, driving market expansion.

Threat:

Data privacy & security concerns

Genomic data is highly sensitive and contains information about an individual's unique genetic makeup, predispositions to diseases, and potentially other personal traits. The risk of unauthorized access to genomic data raises concerns about the misuse of sensitive information. If genomic data falls into the wrong hands, it could be exploited for various purposes, including identity theft, insurance discrimination, or other malicious activities. Failure to adequately address these concerns can impede the growth of the whole genome sequencing market.

COVID-19 Impact

The covid pandemic had a neutral effect on the whole genome sequencing market. The pandemic highlighted the role that genetics plays in comprehending and preventing infectious illnesses. Whole genome sequencing has been used by researchers all around the world to examine the genetic composition and evolutionary history of the SARS-CoV-2 virus. This lightened the significance of genetics in personalized treatment. On the other hand, the market was momentarily impacted by variables including the interruption of supply networks and changes in research objectives.

The precision medicine segment is expected to be the largest during the forecast period

The precision medicine segment is estimated to have a lucrative. Precision medicine involves tailoring medical treatment and healthcare decisions to the individual characteristics of each patient. Whole genome sequencing plays a central role in precision medicine, providing a comprehensive analysis of an individual's entire genome. It helps to optimize drug selection and dosage. Additionally, it offers cost effective treatments, patient empowerment and personalized care plans which accelerates the segment growth.

The research centers segment is expected to have the highest CAGR during the forecast period

The research centers segment is anticipated to witness the highest CAGR growth during the forecast period, due to the advancements in a wide range of research fields. WGS offers a myriad of uses and benefits in research centers, contributing to the significant understanding of genetics, genomics, and various biological processes. It also provides critical information for understanding disease mechanisms, identifying potential therapeutic targets, and developing personalized treatment approaches.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the growing investment in R&D activities. The Asia-Pacific region has experienced substantial growth in the biotechnology and healthcare sectors. Governments have initiated funding programs and supportive policies to encourage the adoption of genomic technologies for research and clinical applications. The region's diverse population along with growing generic disorders is boosting the market's expansion.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the rising government funding. The region hosts numerous leading biotechnology & pharmaceutical companies focused on genomics and personalized medicine. Consumers in North America have shown interest in learning about their ancestry, predisposition to certain health conditions, and other genomic information. Further, the rising innovation in whole genome sequencing and its application in cancer treatments are thereby augmenting the regional market trends.

Key players in the market:

Some of the key players profiled in the Whole Genome Sequencing Market include Siemens Healthineers, Thermo Fisher Scientific Inc, F. Hoffmann-La Roche Ltd, Danaher Corporation, Agilent Technologies Inc, Illumina Inc, Complete Genomics, QIAGEN N.V., GeneDx, Merck KGaA, Abbott, Eurofins Scientific, Oxford Nanopore Technologies, Bio-Rad Laboratories, Inc and Macrogens Inc.

Key Developments:

In October 2023, Oxford Nanopore Technologies and Fabric Genomics collaborated to launch an integrated whole-genome sequencing solution to advance the future of paediatric patient care. The joint solution, which will be commercially available for deployment in CLIA/CAP labs, will support use of nanopore sequencing in neonatal/pediatric intensive care units.

In October 2023, Complete Genomics, a pioneering genomic sequencing company, launched its DNBSEQ-T20x2* product, which reduced the cost of whole genome sequencing to less than $100 per 30X WGS.

In August 2023, GeneDx and PacBio announced research collaboration with the University of Washington to study the capabilities of HiFi long-read whole genome sequencing (WGS) to increase diagnostic rates in pediatric patients with genetic conditions.

Products Covered:

  • Consumables
  • Instruments
  • Services

Types Covered:

  • Small Whole Genome Sequencing
  • Large Whole Genome Sequencing

Workflows Covered:

  • Data Analysis
  • Sequencing
  • Pre-Sequencing

Technologies Covered:

  • Sanger Sequencing
  • Microarray
  • Polymerase Chain Reaction
  • Next Generation Sequencing
  • Other Technologies

Applications Covered:

  • Drug Discovery & Development
  • Diagnostics
  • Precision Medicine
  • Other Applications

End Users Covered:

  • Academic Institutes
  • Hospitals & Clinics
  • Research Centers
  • Pharmaceutical & Biotechnology Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Whole Genome Sequencing Market, By Product

  • 5.1 Introduction
  • 5.2 Consumables
  • 5.3 Instruments
  • 5.4 Services

6 Global Whole Genome Sequencing Market, By Type

  • 6.1 Introduction
  • 6.2 Small Whole Genome Sequencing
  • 6.3 Large Whole Genome Sequencing

7 Global Whole Genome Sequencing Market, By Workflow

  • 7.1 Introduction
  • 7.2 Data Analysis
  • 7.3 Sequencing
  • 7.4 Pre-Sequencing

8 Global Whole Genome Sequencing Market, By Technology

  • 8.1 Introduction
  • 8.2 Sanger Sequencing
  • 8.3 Microarray
  • 8.4 Polymerase Chain Reaction
  • 8.5 Next Generation Sequencing
  • 8.6 Other Technologies

9 Global Whole Genome Sequencing Market, By Application

  • 9.1 Introduction
  • 9.2 Drug Discovery & Development
  • 9.3 Diagnostics
  • 9.4 Precision Medicine
  • 9.5 Other Applications

10 Global Whole Genome Sequencing Market, By End User

  • 10.1 Introduction
  • 10.2 Academic Institutes
  • 10.3 Hospitals & Clinics
  • 10.4 Research Centers
  • 10.5 Pharmaceutical & Biotechnology Companies
  • 10.6 Other End Users

11 Global Whole Genome Sequencing Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Siemens Healthineers
  • 13.2 Thermo Fisher Scientific Inc
  • 13.3 F. Hoffmann-La Roche Ltd
  • 13.4 Danaher Corporation
  • 13.5 Agilent Technologies Inc
  • 13.6 Illumina Inc
  • 13.7 Complete Genomics
  • 13.8 QIAGEN N.V.
  • 13.9 GeneDx
  • 13.10 Merck KGaA
  • 13.11 Abbott
  • 13.12 Eurofins Scientific
  • 13.13 Oxford Nanopore Technologies
  • 13.14 Bio-Rad Laboratories, Inc
  • 13.15 Macrogens Inc

List of Tables

  • Table 1 Global Whole Genome Sequencing Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Whole Genome Sequencing Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Whole Genome Sequencing Market Outlook, By Consumables (2021-2030) ($MN)
  • Table 4 Global Whole Genome Sequencing Market Outlook, By Instruments (2021-2030) ($MN)
  • Table 5 Global Whole Genome Sequencing Market Outlook, By Services (2021-2030) ($MN)
  • Table 6 Global Whole Genome Sequencing Market Outlook, By Type (2021-2030) ($MN)
  • Table 7 Global Whole Genome Sequencing Market Outlook, By Small Whole Genome Sequencing (2021-2030) ($MN)
  • Table 8 Global Whole Genome Sequencing Market Outlook, By Large Whole Genome Sequencing (2021-2030) ($MN)
  • Table 9 Global Whole Genome Sequencing Market Outlook, By Workflow (2021-2030) ($MN)
  • Table 10 Global Whole Genome Sequencing Market Outlook, By Data Analysis (2021-2030) ($MN)
  • Table 11 Global Whole Genome Sequencing Market Outlook, By Sequencing (2021-2030) ($MN)
  • Table 12 Global Whole Genome Sequencing Market Outlook, By Pre-Sequencing (2021-2030) ($MN)
  • Table 13 Global Whole Genome Sequencing Market Outlook, By Technology (2021-2030) ($MN)
  • Table 14 Global Whole Genome Sequencing Market Outlook, By Sanger Sequencing (2021-2030) ($MN)
  • Table 15 Global Whole Genome Sequencing Market Outlook, By Microarray (2021-2030) ($MN)
  • Table 16 Global Whole Genome Sequencing Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
  • Table 17 Global Whole Genome Sequencing Market Outlook, By Next Generation Sequencing (2021-2030) ($MN)
  • Table 18 Global Whole Genome Sequencing Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 19 Global Whole Genome Sequencing Market Outlook, By Application (2021-2030) ($MN)
  • Table 20 Global Whole Genome Sequencing Market Outlook, By Drug Discovery & Development (2021-2030) ($MN)
  • Table 21 Global Whole Genome Sequencing Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 22 Global Whole Genome Sequencing Market Outlook, By Precision Medicine (2021-2030) ($MN)
  • Table 23 Global Whole Genome Sequencing Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 24 Global Whole Genome Sequencing Market Outlook, By End User (2021-2030) ($MN)
  • Table 25 Global Whole Genome Sequencing Market Outlook, By Academic Institutes (2021-2030) ($MN)
  • Table 26 Global Whole Genome Sequencing Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 27 Global Whole Genome Sequencing Market Outlook, By Research Centers (2021-2030) ($MN)
  • Table 28 Global Whole Genome Sequencing Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 29 Global Whole Genome Sequencing Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.